MTX214

**MTX214** is an undisclosed **long-acting injectable formulation** being developed by **Midatech** under a collaboration agreement with the European affiliate of a global healthcare company, identified in company disclosures as **Janssen**. Publicly available information indicates that Midatech manufactured and delivered **proof-of-concept formulations** of MTX214 for partner-led **in vivo studies**, but the active pharmaceutical ingredient, molecular target, mechanism of action, indication, dosage form specifics, and route of administration have not been publicly disclosed. Based on the available evidence, MTX214 appears to be a proprietary formulation program rather than a fully characterized named drug product.